EUVIMEDEUVIMED entdecken
Crossref

Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay

Akira Fujiyama, Yuichiro Arima, Rina Inoue, Naoto Kuyama, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Yasushi Matsuzawa, Eiichiro Yamamoto, Yasuhiro Izumiya, Mariko Komatsu und 2 weitere

Thrombosis and Haemostasis · 2026-11 · 126 (11) · 1166-1178

DOI: 10.1055/a-2751-8379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 08.12.2025. Verfasst von Akira Fujiyama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Cardiology Laboratory, International Research Center for Medical Science (IRCMS), Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Thrombin, Blood Coagulation, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Grant-in-Aid for Scientific Research, Japan Agency for Medical Research and Development (AMED), Grant for Precursory Research for Embryonic Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Initial thrombin (FIIa) generation is a critical trigger for the amplification and propagation phases of coagulation, driven by two distinct pathways: the tissue factor (TF)-driven and the FVIIIa/FIXa-dependent pathways. However, the clinical utility of measuring initial thrombin generation (ITG) as a marker of thrombogenicity or as a tool to monitor the efficacy of oral anti-FXa therapy remains uncertain. ITG driven by TF and the FVIIIa/FIXa complex was first measured in plasma samples from healthy adults (n = 40). This was followed by an analysis of ITG profiles in 771 consecutive patients with cardiovascular diseases to evaluate the effects of anticoagulant therapy and clinical characteristics. Of the 771 patients studied, 169 were receiving direct oral anticoagulants (DOACs). DOAC treatment significantly suppressed thrombin generation via both TF-driven and FVIIIa/FIXa-dependent pathways. Receiver operating characteristic (ROC) analysis confirmed the strong discriminatory power of both pathways for detecting DOAC use (FVIIIa/FIXa: AUC 0.863, 95% CI: 0.826–0.900; TF: AUC 0.887, 95% CI: 0.856–0.917; both p values < 0.0001). Among patients not on anticoagulants, logistic regression revealed that dialysis was associated with reduced thrombin generation through both pathways. Furthermore, chronic kidney disease and active cancer were specifically associated with diminished TF-driven thrombin generation. The ITG potentials driven by TF- and FVIIIa/FIXa-dependent pathways represent promising biomarkers for evaluating anticoagulant efficacy. Moreover, the distinct influence of pathological conditions on each pathway underscores the need to account for specific disease contexts when assessing coagulation potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombinBlood CoagulationCardiovascular DiseasesHumansFemaleMaleBlood Coagulation TestsMiddle AgedAgedThromboplastinAnticoagulantsAdultAdministration, OralBiomarkersROC CurveAged, 80 and overFactor IXaFactor Xa InhibitorsPredictive Value of Tests

Substanzen

ThrombinThromboplastinAnticoagulantsBiomarkersFactor IXaFactor Xa Inhibitors

Autor:innen und Institutionen

  • Developmental Cardiology Laboratory, International Research Center for Medical Science (IRCMS), Kumamoto University, Kumamoto, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Center for Metabolic Regulation of Healthy Aging, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Anatomy, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Thrombo Translational Research Lab Inc., Kumamoto, Japan.
  • Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto, Japan.

ORCID-Profile: Yuichi Kamikubo

Förderung

  • Grant-in-Aid for Scientific Research
  • Japan Agency for Medical Research and Development (AMED)
  • Grant for Precursory Research for Embryonic Science and Technology
  • TAUNS Laboratories, Inc.
  • Thrombo Translational Research Labo Inc.

Zitieren

APA

Fujiyama, A., Arima, Y., Inoue, R., Kuyama, N., Yamamoto, M., Hirakawa, K., Ishii, M., Hanatani, S., Matsuzawa, Y., Yamamoto, E., Izumiya, Y., Komatsu, M., Kamikubo, Y., & Tsujita, K. (2026). Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay. Thrombosis and Haemostasis, 126(11), 1166-1178. https://doi.org/10.1055/a-2751-8379

Vancouver

Fujiyama A, Arima Y, Inoue R, Kuyama N, Yamamoto M, Hirakawa K, et al. Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay. Thrombosis and Haemostasis. 2026;126(11):1166-1178. doi:10.1055/a-2751-8379

BibTeX
@article{Fujiyama2026,
  author = {Fujiyama, Akira and Arima, Yuichiro and Inoue, Rina and Kuyama, Naoto and Yamamoto, Masahiro and Hirakawa, Kyoko and Ishii, Masanobu and Hanatani, Shinsuke and Matsuzawa, Yasushi and Yamamoto, Eiichiro and Izumiya, Yasuhiro and Komatsu, Mariko and Kamikubo, Yuichi and Tsujita, Kenichi},
  title = {Profiling Initial Thrombin Generation in Cardiovascular Disease Using a High Sensitivity Coagulation Assay},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {11},
  pages = {1166--1178},
  doi = {10.1055/a-2751-8379}
}
Kostenlos starten →